Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Express Scripts
Deloitte
QuintilesIMS
Cantor Fitzgerald
Farmers Insurance
Baxter
McKinsey
McKesson
Fish and Richardson

Generated: June 25, 2018

DrugPatentWatch Database Preview

Details for Patent: 9,566,239

« Back to Dashboard

Title:Pharmaceutical formulations for dry powder inhalers
Abstract: A powder for use in a dry powder inhaler comprises: i) a fraction of fine particle size constituted by a mixture of physiologically acceptable excipient and an additive; ii) a fraction of coarse particles; and iii) at least one active ingredient. The powder is suitable for efficacious delivery of active ingredients into the low respiratory tract of patients suffering from pulmonary diseases such as asthma. In particular, the invention provides a formulation to be administered as dry powder for inhalation which is freely flowable, can be produced in a simple way, is physically and chemically stable and capable of delivering accurate doses and/or high fine particle fraction of low strength active ingredients by using a high- or medium resistance device.
Inventor(s): Staniforth; John Nicholas (Bath, GB), Morton; David Alexander Vodden (Bath, GB), Gill; Rajbir (Wiltshire, GB), Brambilla; Gaetano (Parma, IT), Musa; Rossella (Parma, IT), Ferrarini; Lorenzo (Parma, IT)
Assignee: VECTURA LIMITED (Chippenham, Wiltshire, GB)
Filing Date:Sep 22, 2014
Application Number:14/492,156
Claims:1. A powder for use in a dry powder inhaler, the powder comprising: i) a fraction of fine particle size constituted of a mixture prepared by co-micronising a physiologically acceptable excipient and an additive, the mixture having a mean particle size of less than 35 .mu.m; ii) a fraction of coarse particles constituted of a physiologically acceptable carrier having a diameter of at least 100 .mu.m; and iii) at least one active ingredient having a particle size of less than 10 .mu.m; said mixture (i) being composed of up to 99% by weight of particles of the physiologically acceptable excipient and at least 1% by weight of additive and a ratio between the fine excipient particles and the coarse particles being between 1:99 and 40:60% by weight, and wherein the additive partially coats the surfaces of both the physiologically acceptable excipient and the coarse particles.

2. A powder according to claim 1, which is in the form of `hard pellets`, which are spherical or semi-spherical units whose core is made of coarse particles.

3. A powder according to claim 1, wherein the mixture (i) is composed of from 90 to 99% by weight of the physiologically acceptable excipient and from 1 to 10% by weight of the additive.

4. A powder according to claim 2, wherein the mixture (i) is composed of from 90 to 99% by weight of the physiologically acceptable excipient and from 1 to 10% by weight of the additive.

5. A powder according to any one of claim 1-3 or 4, wherein the ratio between the fraction of fine particle size and the fraction of coarse particles is at least 10:90.

6. A powder according to any one of claim 1-3 or 4, wherein the ratio between the fraction of fine particle size and the fraction of coarse particles is comprised between 15:85 and 30:70% by weight.

7. A powder according to any one of claim 1-3 or 4, wherein the fraction of coarse particles is constituted of a physiologically acceptable excipient which has a particle size of 100 to 400 .mu.m.

8. A powder according to any one of claim 1-3 or 4, in which the particle size of the mixture (i) is less than 15 .mu.m.

9. A powder according to any one of claim 1-3 or 4, in which the fraction of fine particle size is composed of 98% by weight of the physiologically acceptable excipient and 2% by weight of the additive and the ratio between the fraction of fine particle size and the fraction of coarse particles is 10:90% by weight.

10. A powder according to any one of claim 1-3 or 4, in which the coarse carrier particles have a tapped density of not exceeding 0.7 g/cm3.

11. A powder according to any one of claim 1-3 or 4, in which the coarse carrier particles have a bulk density as measured by mercury porosimetry of not exceeding 0.6 g/cm3.

12. A powder according to any one of claim 1-3 or 4, wherein the additive is selected from the group consisting of lubricants, antiadherents and glidants.

13. A powder according to any one of claim 1-3 or 4, wherein the additive is magnesium stearate.

14. A powder according to any one of claim 1-3 or 4, wherein the physiologically acceptable excipient is one or more crystalline sugars.

15. A powder according to any one of claim 1-3 or 4, wherein the physiologically acceptable excipient is a-lactose monohydrate.

16. A powder according to any one of claim 1-3 or 4, wherein the at least one active ingredient has a particle size less than 6 .mu.m.

17. A powder according to any one of claim 1-3 or 4, wherein the additive is magnesium stearate and the active ingredient(s) is (are) not selected from budesonide and its epimers, formoterol, TA2005 and its stereoisomers, salts thereof, and combinations thereof.

18. A powder according to any one of claim 1-3 or 4, comprising more than 5% based on the total weight of the formulation, of particles of aerodynamic diameter less than 20 .mu.m, the formulation having a flowability index of 12 mm or less, wherein flowability is evaluated using a FLODEX (registered trademark) tester.

19. A powder according to any one of claim 1-3 or 4, comprising more than 10% based on the total weight of the formulation, of particles of aerodynamic diameter less than 20 .mu.m, the formulation having a flowability index of 12 mm or less, wherein flowability is evaluated using a FLODEX (registered trademark) tester.

20. A process for making a powder according to any one of claim 1-3 or 4: wherein step i) involves co-micronising particles of the physiologically acceptable excipient and particles of the additive so as to significantly reduce their particle size; wherein step ii) involves spheronising by mixing the resulting mixture with the fraction of coarse particles such that mixture particles adhere to the surface of the coarse particles; and wherein step iii) involves adding by mixing particles of the active ingredient to the spheronised particles from step ii).

21. A process according to claim 20 wherein step i) is carried out using a jet mill.

22. A process for making a powder according to any one of claim 1-3 or 4, wherein step i) involves co-micronising particles of the physiologically acceptable excipient and particles of the additive so as to significantly reduce their particle size; wherein step ii) involves spheronising by mixing the resulting mixture with the fraction of coarse particles such that mixture particles adhere to the surface of the coarse particles; and wherein step iii) involves adding by mixing particles of the active ingredient to the spheronised particles from step ii); wherein the additive particles at least partially coat the surface of the particles of the pharmaceutically acceptable excipient.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Farmers Insurance
Colorcon
Mallinckrodt
Queensland Health
McKinsey
Baxter
AstraZeneca
Citi
Federal Trade Commission

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.